HC Wainwright Has Strong Forecast for enGene FY2026 Earnings

enGene Holdings Inc. (NASDAQ:ENGN) – Equities research analysts at HC Wainwright raised their FY2026 earnings estimates for shares of enGene in a report issued on Tuesday, September 8th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of ($1.89) for the year, up from their prior estimate of ($1.95). HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock. The consensus estimate for enGene’s current full-year earnings is ($1.83) per share. HC Wainwright also issued estimates for enGene’s Q4 2026 earnings at ($0.55) EPS, FY2027 earnings at ($1.98) EPS, FY2028 earnings at ($1.76) EPS and FY2029 earnings at ($0.76) EPS.

enGene (NASDAQ:ENGN) last posted its earnings results on Tuesday, September 8th. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.04).

Other equities analysts also recently issued research reports about the company. Weiss Ratings restated a “sell (e+)” rating on shares of enGene in a research report on Wednesday, August 12th. UBS Group cut their price objective on enGene from $9.00 to $2.00 and set a “neutral” rating for the company in a report on Thursday, May 14th. Citizens Jmp reaffirmed a “market perform” rating on shares of enGene in a report on Wednesday. Citigroup reissued a “market perform” rating on shares of enGene in a report on Wednesday. Finally, Wall Street Zen raised shares of enGene from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Four investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, enGene has an average rating of “Hold” and an average price target of $11.05.

enGene Stock Down 4.3%

NASDAQ ENGN opened at $1.77 on Friday. enGene has a 1-year low of $1.40 and a 1-year high of $12.25. The company has a market capitalization of $118.57 million, a price-to-earnings ratio of -1.57 and a beta of -0.28. The stock’s 50 day moving average is $1.83 and its two-hundred day moving average is $3.93. The company has a current ratio of 10.21, a quick ratio of 12.57 and a debt-to-equity ratio of 0.11.

Institutional Investors Weigh In On enGene

A number of hedge funds have recently added to or reduced their stakes in the stock. Cresset Asset Management LLC acquired a new stake in enGene in the 2nd quarter valued at about $36,000. Paloma Partners Management Co bought a new stake in shares of enGene during the second quarter valued at approximately $38,000. Raymond James Financial Inc. increased its holdings in shares of enGene by 383.6% in the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock valued at $68,000 after purchasing an additional 7,932 shares in the last quarter. Jump Financial LLC bought a new position in enGene in the 4th quarter worth approximately $121,000. Finally, Millennium Management LLC raised its position in enGene by 57.3% in the 3rd quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock worth $140,000 after purchasing an additional 7,472 shares during the last quarter. Institutional investors own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.